Roivant Sciences (ROIV) PT Raised to $18 at H.C. Wainwright, 'brepocitinib has blockbuster potential'

H.C. Wainwright analyst Douglas Tsao raised the price target on Roivant Sciences (NASDAQ: ROIV) to $18.00 (from $17.00) while maintaining a Buy rating.

The analyst commented: 'Across the NIU and dermatomyositis, we believe brepocitinib has blockbuster potential. We raise our price target to $18 from $17 with this pipeline success as well as the company's announcement that it is buying back the shares held by Sumitomo Pharma for $648M, reducing the share count by ~9%.'

You May Also Be Interested In

• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker